Industrial

What's the Tariff on Pharmaceuticals?

Active pharmaceutical ingredients from India and China.

💡
The 10% tariff on Pharmaceuticals is paid by American importers, not foreign manufacturers. Your Rx drug ingredients now costs $110 instead of $100 — that's $10 more, or 10% of the sticker price going directly to tariff taxes.

Current Tariff Rate

10%

Pre-2025 Rate

0%

Rate Increase

+10pp

Price Impact

+10%

+$10

Real-World Price Impact

Before Tariffs

$100

Rx drug ingredients

After Tariffs

$110

Rx drug ingredients

That's $10 more per unit — a 10% price increase paid by the American buyer.

Note: Price estimates assume full tariff pass-through to consumers. Actual retail prices may vary — manufacturers may absorb some costs, shift production, or adjust margins.

The Story Behind This Tariff

Pharmaceutical tariffs expose America's dangerous dependency on foreign drug manufacturing — a vulnerability laid bare during COVID-19 supply chain disruptions. India produces 40% of US generic drug supply, while China manufactures 80% of active pharmaceutical ingredients (APIs) used globally. The 10% Section 122 tariff on finished drugs and ingredients is deliberately modest — policymakers fear the public health consequences of making medications more expensive. However, even 10% on essential medications creates real costs: insulin, blood pressure drugs, antibiotics, and cancer treatments all rely on imported APIs. The tariff's stated goal is encouraging domestic API production, but building pharmaceutical manufacturing capacity requires 5-7 years of facility construction and FDA approval. In the interim, the tariff functions as a tax on sick people. Generic drug companies operate on razor-thin 3-5% margins, meaning even small tariffs may force some generics off the market entirely.

📦 Supply Chain

Primary Origin

IN

Made in USA

28%

Import Volume

$195B

Alternatives

Ireland (Pfizer, big pharma), domestic expansion (slow)

📅 Tariff Timeline

2018

Pharmaceuticals excluded from Section 301

0%

2020

COVID exposes API supply chain vulnerability

0%

2025

Section 122 baseline applied to all pharma imports

10%

👥 Consumer Impact

Households Affected

130M

Annual Cost Per Household

$120

💡 Did You Know?

  • China manufactures 80% of the world's active pharmaceutical ingredients — the raw materials in nearly every pill Americans take
  • India produces 40% of US generic drugs but sources 70% of its own APIs from China, creating a dependency chain
  • The US cannot currently manufacture common antibiotics like amoxicillin domestically — the last US penicillin plant closed in 2004

Tariff Details

HTS Code
3004.90
Current Rate
10%
Pre-2025 Rate
0%
Tariff Type
Section 122

Legal Authority

Section 122 (Balance of Payments)

Effective: April 2025

Baseline 10% tariff on imports to address balance of payments

The tariff on Pharmaceuticals is paid by the American importer at the port of entry and passed through to consumers as higher retail prices. The foreign manufacturer does not pay the tariff.

Who Actually Pays This Tariff?

Despite claims that tariffs are paid by foreign countries, the 10% tariff on Pharmaceuticals is paid by American importers — US companies that purchase these goods from abroad. The cost is then passed to American consumers through higher retail prices.

  • ✓ The foreign seller receives the same price as before
  • ✓ The US importer pays 10% of the customs value to CBP
  • ✓ The retailer marks up the higher landed cost
  • ✓ You pay more at the register: $100 → $110

Related Products in Industrial

🔍 Dig Deeper

See the Full Picture

Tariffs affect thousands of products. See how much they're costing your household.